https://www.pharmaradar360.com/article/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-min-70d84d711f698d62Pharma Surgeen2026-07-07T11:35:00.000ZVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Managementhttps://www.pharmaradar360.com/article/field-safety-notices-29-june-to-03-july-2026-f51c6e309cfc832ePharma Surgeen2026-07-07T11:14:05.000ZField Safety Notices: 29 June to 03 July 2026https://www.pharmaradar360.com/article/what-do-i-need-to-know-about-daraxonrasib-the-new-treatment-for-pancreatic-cance-6b36c4a5afd43e73Pharma Surgeen2026-07-07T11:09:30.000ZWhat do I need to know about daraxonrasib, the new treatment for pancreatic cancer?https://www.pharmaradar360.com/article/fda-backs-single-phase-3-trial-for-alterity-s-msa-drug-ath434-5f6f015a20e0b674Pharma Surgeen2026-07-07T11:05:00.000ZFDA backs single Phase 3 trial for Alterity’s MSA drug ATH434https://www.pharmaradar360.com/article/axsome-starts-phase-3-adhd-trial-in-children-enrolling-468-patients-6a6061d761fd5388Pharma Surgeen2026-07-07T11:00:00.000ZAxsome starts Phase 3 ADHD trial in children, enrolling 468 patientshttps://www.pharmaradar360.com/article/annovis-enrolls-850-patients-in-phase-3-alzheimer-s-study-0771ac8bbf58adc0Pharma Surgeen2026-07-07T11:00:00.000ZAnnovis enrolls 850 patients in Phase 3 Alzheimer’s studyhttps://www.pharmaradar360.com/article/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-pha-47f47641776a4e99Pharma Surgeen2026-07-07T11:00:00.000ZKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535https://www.pharmaradar360.com/article/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-66d4f99c8ab8984aPharma Surgeen2026-07-07T11:00:00.000ZAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Diseasehttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-12432027a49613e7Pharma Surgeen2026-07-07T10:58:45.000ZDHSC spending over £25,000https://www.pharmaradar360.com/article/shanghai-hong-kong-bootcamp-selects-ai-and-biotech-projects-3f642eeea2ab252dPharma Surgeen2026-07-07T10:58:43.000ZShanghai-Hong Kong Bootcamp Selects AI and Biotech Projectshttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-february-2026-b20ca4cb325bef21Pharma Surgeen2026-07-07T10:58:06.000ZDHSC: spending over £25,000, February 2026https://www.pharmaradar360.com/article/brandon-capital-scores-its-biggest-return-ever-with-2-1bn-biotech-acquisition-426c1053b54c6ee8Pharma Surgeen2026-07-07T10:34:17.000ZBrandon Capital scores its biggest return ever with $2.1bn biotech acquisitionhttps://www.pharmaradar360.com/article/rcs-intnl-biotechnology-portfolio-company-crinetics-acquired-by-vertex-3607d0b29e43fdcdPharma Surgeen2026-07-07T10:34:02.000ZRCS - Intnl. Biotechnology - Portfolio company Crinetics acquired by Vertexhttps://www.pharmaradar360.com/article/decision-advertising-investigations-june-2026-a316cedf64c3ced3Pharma Surgeen2026-07-07T10:30:42.000ZDecision: Advertising investigations: June 2026https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-1895e594079472ebPharma Surgeen2026-07-07T10:30:12.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/compass-pathways-says-second-psilocybin-trial-kept-depression-benefit-for-6-mont-6b2f2d329a20da71Pharma Surgeen2026-07-07T10:30:00.000ZCompass Pathways says second psilocybin trial kept depression benefit for 6 monthshttps://www.pharmaradar360.com/article/compass-pathways-announces-six-month-data-from-second-phase-3-trial-confirming-r-273b8261b66b5a2dPharma Surgeen2026-07-07T10:30:00.000ZCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profilehttps://www.pharmaradar360.com/article/the-changing-reality-of-pharmaceutical-commercialization-in-a-cold-chain-driven-bb4990ff8d52755dPharma Surgeen2026-07-07T10:10:16.000ZThe Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Markethttps://www.pharmaradar360.com/article/cmg-pharmaceutical-co-ltd-announced-that-it-has-received-krw-45-billion-in-fundi-8762af8d7552bd85Pharma Surgeen2026-07-07T10:05:40.000ZCMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.https://www.pharmaradar360.com/article/fda-outlines-single-phase-3-trial-plan-for-alterity-nasdaq-athe-ath434-e22cfc4168b03803Pharma Surgeen2026-07-07T10:04:06.000ZFDA outlines single Phase 3 trial plan for Alterity (NASDAQ: ATHE) ATH434https://www.pharmaradar360.com/article/west-to-host-second-quarter-2026-conference-call-c1f1a3d6d5ebf729Pharma Surgeen2026-07-07T10:00:00.000ZWest to Host Second-Quarter 2026 Conference Callhttps://www.pharmaradar360.com/article/uk-biotechs-struggling-to-access-finance-as-scale-up-concerns-grow-f52d1d5556bb95f0Pharma Surgeen2026-07-07T09:56:15.000ZUK biotechs struggling to access finance as scale-up concerns growhttps://www.pharmaradar360.com/article/why-maharashtra-fda-banned-compulsory-hospital-pharmacy-purchases-b98794707a5a1a06Pharma Surgeen2026-07-07T09:46:36.000ZWhy Maharashtra FDA Banned Compulsory Hospital Pharmacy Purchaseshttps://www.pharmaradar360.com/article/how-do-analysts-rate-this-biotech-focused-on-chronic-inflammatory-diseases-f520bec606c17ccdPharma Surgeen2026-07-07T09:33:45.000ZHow Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?https://www.pharmaradar360.com/article/french-clinical-stage-biotech-s-uc-drug-faces-best-in-disease-doubts-as-analyst-d86c752ba559c435Pharma Surgeen2026-07-07T09:33:45.000ZFrench Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filinghttps://www.pharmaradar360.com/article/sanyou-and-baiyunshan-xihe-sign-radiopharma-deal-b033b4660a487d03Pharma Surgeen2026-07-07T09:32:13.000ZSanyou and Baiyunshan Xihe sign radiopharma dealhttps://www.pharmaradar360.com/article/krazati-combo-misses-phase-iii-mark-in-colorectal-cancer-cf58bcd7ad2bf903Pharma Surgeen2026-07-07T09:32:13.000ZKrazati combo misses Phase III mark in colorectal cancerhttps://www.pharmaradar360.com/article/rare-japan-ip-court-opinion-request-probes-pharmaceutical-patent-rules-67d7f48bc86addcbPharma Surgeen2026-07-07T09:12:00.000ZRare Japan IP Court opinion request probes pharmaceutical patent ruleshttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7Pharma Surgeen2026-07-07T09:10:38.000ZWorking for DHSChttps://www.pharmaradar360.com/article/rotavirus-vaccination-programme-information-for-healthcare-practitioners-53785302d776c5f3Pharma Surgeen2026-07-07T09:02:11.000ZRotavirus vaccination programme: information for healthcare practitionershttps://www.pharmaradar360.com/article/cereno-scientific-completes-all-dosing-and-participant-visits-in-cs014-s-fda-ali-c871d670a450d89dPharma Surgeen2026-07-07T09:00:00.000ZCereno Scientific Completes All Dosing and Participant Visits in CS014’s FDA-Aligned PK-Bridging Study, Advancing Capital-Efficient Path Toward Phase IIb in PH-ILDhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-july-2026-5cb6f6902269e1ecPharma Surgeen2026-07-07T08:43:44.000ZUK Clinical Research Delivery key performance indicators: data to July 2026https://www.pharmaradar360.com/article/woodberry-packaging-acquires-medica-and-curtis-strengthening-its-position-in-pha-8078b9fe1ab6d86ePharma Surgeen2026-07-07T08:40:23.000ZWoodberry Packaging acquires Medica and Curtis, strengthening its position in pharmaceutical and personal care packaginghttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-5ce9d540fae1527cPharma Surgeen2026-07-07T08:40:01.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-95407ca4abeca4e9Pharma Surgeen2026-07-07T08:38:01.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/polio-global-eradication-nac-and-environmental-surveillance-28a88d7a1d6b4d94Pharma Surgeen2026-07-07T08:34:51.000ZPolio: global eradication, NAC and environmental surveillancehttps://www.pharmaradar360.com/article/2026-b7f2bfa19e6fb750Pharma Surgeen2026-07-07T08:31:22.000ZΕπιστημονικές εκδηλώσεις εσωτερικού Α΄ εξαμήνου 2026https://www.pharmaradar360.com/article/guidance-clinical-trials-for-medicines-roles-and-responsibilities-3e0684843843bbdcPharma Surgeen2026-07-07T08:23:12.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/as-ai-sectors-cooldown-biotech-breaks-out-6-stocks-quietly-outperform-feeb27629042d7bcPharma Surgeen2026-07-07T08:20:26.000ZAs AI Sectors Cooldown, BioTech Breaks Out: 6 Stocks Quietly Outperformhttps://www.pharmaradar360.com/article/biotech-layoffs-in-2026-trends-triggers-and-what-s-at-stake-7c47efcd2cd6ebbePharma Surgeen2026-07-07T08:17:47.000ZBiotech Layoffs in 2026: Trends, Triggers, and What’s at Stakehttps://www.pharmaradar360.com/article/decision-doxecitine-and-doxribtimine-in-the-treatment-of-thymidine-kinase-2-defi-98729cfb4ffb37fcPharma Surgeen2026-07-07T08:15:25.000ZDecision: Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)https://www.pharmaradar360.com/article/why-customer-experience-centers-are-becoming-practical-infrastructure-for-life-s-18f4fb049a82176cPharma Surgeen2026-07-07T08:03:44.000ZWhy Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europehttps://www.pharmaradar360.com/article/your-medicine-bottle-is-getting-a-qr-code-and-it-could-actually-save-your-life-6899e9309924dedaPharma Surgeen2026-07-07T08:00:14.000ZYour Medicine Bottle Is Getting a QR Code — and It Could Actually Save Your Lifehttps://www.pharmaradar360.com/article/biovica-expands-master-services-agreement-with-a-current-customer-a-leading-glob-60d72aa05adb38a7Pharma Surgeen2026-07-07T08:00:00.000ZBiovica expands Master Services Agreement with a current customer, a leading global pharmaceutical company, to support next-generation oncology development.https://www.pharmaradar360.com/article/abl-bio-targets-december-phase-3-start-for-abl111-in-gastric-cancer-cab24dfeb858d0bfPharma Surgeen2026-07-07T07:43:37.000ZABL Bio targets December phase 3 start for ABL111 in gastric cancerhttps://www.pharmaradar360.com/article/korean-nf2-drug-candidate-trineumin-wins-fda-rare-pediatric-disease-designation-f49644b6fd0506d0Pharma Surgeen2026-07-07T07:43:14.000ZKorean NF2 drug candidate Trineumin wins FDA rare pediatric disease designationhttps://www.pharmaradar360.com/article/maharashtra-fda-cracking-down-on-hospitals-that-force-patients-to-buy-exclusive-579b7a0f0c99c9b0Pharma Surgeen2026-07-07T07:38:39.000ZMaharashtra FDA Cracking Down On Hospitals That Force Patients to Buy Exclusive Prescriptions, Says Tukaram Mundhehttps://www.pharmaradar360.com/article/abl-bio-to-begin-phase-3-clinical-trial-of-abl111-in-december-sanofi-risks-also-d76a7c05cc7e4000Pharma Surgeen2026-07-07T07:18:06.000ZABL Bio to Begin Phase 3 Clinical Trial of 'ABL111' in December... Sanofi Risks Also Resolvedhttps://www.pharmaradar360.com/article/price-to-book-forward-of-jiangsu-cowin-biotech-co-ltd-class-a-sse-688426-22ac643d1b24eb05Pharma Surgeen2026-07-07T07:09:54.000ZPrice to book forward of Jiangsu Cowin Biotech Co., Ltd. Class A – SSE:688426https://www.pharmaradar360.com/article/sustained-release-polymers-market-advances-as-drug-delivery-innovation-reshapes-3cf8b187703c91e1Pharma Surgeen2026-07-07T07:01:55.000ZSustained Release Polymers Market Advances as Drug Delivery Innovation Reshapes Pharmaceutical Formulation Strategies with USD 7.8 Billion in 2036 | Future Market Insightshttps://www.pharmaradar360.com/article/abl-bio-pursues-big-pharma-deals-as-korea-advances-cancer-and-bbb-programs-chosu-4369581b0888c6b6Pharma Surgeen2026-07-07T06:59:00.000ZABL Bio pursues big pharma deals as Korea advances cancer and BBB programs - CHOSUNBIZhttps://www.pharmaradar360.com/article/samjin-pharm-launches-fulvestrant-injection-for-hr-her2-advanced-breast-cancer-55738b181e40e3efPharma Surgeen2026-07-07T06:42:09.000ZSamjin Pharm launches fulvestrant injection for HR+/HER2- advanced breast cancerhttps://www.pharmaradar360.com/article/italy-s-angels-incubators-and-venture-capital-weekly-roundup-news-from-banyan-bi-4cfd345637eec390Pharma Surgeen2026-07-07T06:31:06.000ZItaly’s angels & incubators and venture capital weekly roundup. News from Banyan Biotech, Berrier Capital and morehttps://www.pharmaradar360.com/article/french-gene-therapy-biotech-gets-33m-to-follow-krystal-s-blueprint-c63e060b6fd86bd4Pharma Surgeen2026-07-07T05:30:00.000ZFrench gene therapy biotech gets €33M to follow Krystal’s blueprinthttps://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-46dc70bdb7397099Pharma Surgeen2026-07-07T05:07:02.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/gc-biopharma-wins-approval-for-domestic-phase-3-clinical-trial-of-two-dose-varic-a34fb9abe6db1443Pharma Surgeen2026-07-07T05:06:44.000ZGC Biopharma wins approval for domestic Phase 3 clinical trial of two-dose varicella vaccinehttps://www.pharmaradar360.com/article/roche-presents-new-data-in-alzheimer-s-disease-from-across-its-integrated-pharma-859cacd0e13dbf48Pharma Surgeen2026-07-07T05:00:00.000ZRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIChttps://www.pharmaradar360.com/article/roche-presents-new-data-in-alzheimer-s-disease-from-across-its-integrated-pharma-f051c2312acd4eb2Pharma Surgeen2026-07-07T05:00:00.000ZRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIChttps://www.pharmaradar360.com/article/us-fda-confirms-alterity-s-phase-iii-trial-path-b6a08f225b300d0fPharma Surgeen2026-07-07T04:58:00.000ZUS FDA confirms Alterity’s Phase III trial pathhttps://www.pharmaradar360.com/article/the-clinical-trial-that-supported-tavneos-for-anca-vasculitis-was-just-retracted-b08c08b64d438a01Pharma Surgeen2026-07-07T04:54:42.000ZThe Clinical Trial That Supported Tavneos for ANCA Vasculitis Was Just Retractedhttps://www.pharmaradar360.com/article/drug-discovery-ai-moves-beyond-hype-to-an-r-d-productivity-test-de399667f7a3b694Pharma Surgeen2026-07-07T04:43:32.000ZDrug discovery AI moves beyond hype to an R&D productivity testhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-pci-biotech-holding-asa-ls-a0q2fs-39085cc0e3b2325bPharma Surgeen2026-07-07T04:25:35.000ZPrice to earnings forward of PCI Biotech Holding ASA – LS:A0Q2FShttps://www.pharmaradar360.com/article/matica-biotech-vaxdome-partner-to-advance-antiviral-vaccine-platform-into-clinic-1b8321a66b6e0a87Pharma Surgeen2026-07-07T04:03:43.000ZMatica Biotech, VaxDome partner to advance antiviral vaccine platform into clinichttps://www.pharmaradar360.com/article/three-biotech-stocks-crushed-the-s-p-500-analysts-still-back-just-one-1cf415a0b004cc3ePharma Surgeen2026-07-07T03:32:34.000ZThree Biotech Stocks Crushed the S&P 500 — Analysts Still Back Just Onehttps://www.pharmaradar360.com/article/texas-pushes-forward-with-state-ibogaine-research-program-after-failing-to-find-4ae613fb9cd76c18Pharma Surgeen2026-07-07T03:11:00.000ZTexas pushes forward with state ibogaine research program after failing to find drug company partnerhttps://www.pharmaradar360.com/article/aribio-to-unveil-new-ar1001-data-at-alzheimer-s-conference-998851679b5c101bPharma Surgeen2026-07-07T03:05:29.000ZAriBio to unveil new AR1001 data at Alzheimer's conferencehttps://www.pharmaradar360.com/article/alterity-therapeutics-clears-key-fda-hurdle-for-ath434-phase-3-pathway-7241ff566c6d5df4Pharma Surgeen2026-07-07T03:03:41.000ZAlterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathwayhttps://www.pharmaradar360.com/article/anzen-mhlw-pharmaceuticals-and-medical-devices-safety-information-no-429-posted-d1435f2c2e88bb2fPharma Surgeen2026-07-07T03:00:00.000Z[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.429 postedhttps://www.pharmaradar360.com/article/china-s-national-medical-products-administration-accepts-biologics-license-appli-00dae1ff100e152fPharma Surgeen2026-07-07T02:30:00.000ZChina’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/belite-bio-blte-after-new-phase-3-data-news-and-the-case-for-fair-value-1f609f0996a22856Pharma Surgeen2026-07-07T01:34:36.000ZBelite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Valuehttps://www.pharmaradar360.com/article/us-based-malayali-carves-a-niche-with-knee-treatment-255854012aa5998cPharma Surgeen2026-07-07T01:30:39.000ZUS-based Malayali carves a niche with knee treatmenthttps://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-07T00:52:31.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/vertex-pharmaceuticals-filed-form-8-k-7c7fb8b633423119Pharma Surgeen2026-07-07T00:00:00.000ZVertex Pharmaceuticals filed Form 8-Khttps://www.pharmaradar360.com/article/new-technologies-could-help-cut-years-long-wait-for-endometriosis-diagnosis-says-528e4e37e26bada6Pharma Surgeen2026-07-07T00:00:00.000ZNew technologies could help cut years-long wait for endometriosis diagnosis, says NICEhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-07T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-c4dd42ede001d623Pharma Surgeen2026-07-07T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-dc70e319325b088ePharma Surgeen2026-07-07T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-06a27c44871a176dPharma Surgeen2026-07-07T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-dfd763ce0e2e3295Pharma Surgeen2026-07-07T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-864ce3400be36cb1Pharma Surgeen2026-07-07T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f2ec82ff27baa71ePharma Surgeen2026-07-07T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-8c91b2243be6e6ecPharma Surgeen2026-07-07T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-5597743969d29c98Pharma Surgeen2026-07-07T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-386e4a075c34ba1dPharma Surgeen2026-07-07T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-9ed385263e2bfabcPharma Surgeen2026-07-07T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-a99946acfb034930Pharma Surgeen2026-07-07T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-11f10f6ad40e67d5Pharma Surgeen2026-07-07T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-86ea2faa398ce787Pharma Surgeen2026-07-07T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-7db9b76e6be24d82Pharma Surgeen2026-07-07T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/new-animal-drugs-approval-of-new-animal-drug-applications-withdrawal-of-approval-fec0647368369f3aPharma Surgeen2026-07-07T00:00:00.000ZNew Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsorhttps://www.pharmaradar360.com/article/office-of-the-secretary-notice-of-meeting-c0ba619840c46db4Pharma Surgeen2026-07-07T00:00:00.000ZOffice of the Secretary; Notice of Meetinghttps://www.pharmaradar360.com/article/recission-of-the-national-cancer-institute-clinical-cancer-education-program-reg-be11376bf7623390Pharma Surgeen2026-07-07T00:00:00.000ZRecission of the National Cancer Institute Clinical Cancer Education Program Regulationhttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-benuvia-operations-llc-d13da85284e18846Pharma Surgeen2026-07-07T00:00:00.000ZImporter of Controlled Substances Application: Benuvia Operations, LLC.https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-7de317d9222efac3Pharma Surgeen2026-07-07T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-00497debdfd6bcd2Pharma Surgeen2026-07-07T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-3c67d0de69b46fa0Pharma Surgeen2026-07-07T00:00:00.000ZMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardihttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-ee8f225175e0aad8Pharma Surgeen2026-07-07T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Rural Health Care Services Outreach Program Measures, OMB No. 0906-0009-Revisionhttps://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-230aa57d07ee67a4Pharma Surgeen2026-07-07T00:00:00.000ZNational Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/bausch-health-to-announce-second-quarter-2026-results-on-july-29-2026-d4e5fe23a4eb9c46Pharma Surgeen2026-07-07T00:00:00.000ZBausch Health to Announce Second Quarter 2026 Results on July 29, 2026https://www.pharmaradar360.com/article/patient-centered-prescription-opioid-tapering-methods-280a7f0f0db1e533Pharma Surgeen2026-07-07T00:00:00.000ZPatient-Centered Prescription Opioid Tapering Methodshttps://www.pharmaradar360.com/article/assessment-of-an-educational-intervention-for-embryologists-to-reduce-gamete-and-79626f280681eeb1Pharma Surgeen2026-07-07T00:00:00.000ZAssessment of an educational intervention for embryologists to reduce gamete and embryo misidentification in <i>in vitro</i> fertilization laboratorieshttps://www.pharmaradar360.com/article/peer-review-report-for-barriers-and-facilitators-to-interprofessional-work-in-cl-7825d4ea1854c9fbPharma Surgeen2026-07-07T00:00:00.000ZPeer Review Report For: Barriers and Facilitators to Interprofessional Work in Clinical Settings in Japan: A Systematic Review of Qualitative Research [version 1; peer review: 1 approved with reservations]https://www.pharmaradar360.com/article/outcomes-of-liver-transplantation-in-critically-ill-patients-admitted-to-an-inte-5ab747d8797fda48Pharma Surgeen2026-07-07T00:00:00.000ZOutcomes of liver transplantation in critically ill patients admitted to an intensive care unit: a retrospective studyhttps://www.pharmaradar360.com/article/comparative-study-of-recovery-characteristics-between-remimazolam-anesthesia-wit-00f164b754232019Pharma Surgeen2026-07-07T00:00:00.000ZComparative study of recovery characteristics between remimazolam anesthesia with flumazenil and desflurane anesthesia for closed reduction of nasal bone fracture: a randomized controlled trialhttps://www.pharmaradar360.com/article/detection-of-mycobacterium-tuberculosis-complex-and-differentiation-of-five-comm-70861d531e346985Pharma Surgeen2026-07-07T00:00:00.000ZDetection of Mycobacterium tuberculosis Complex and Differentiation of Five Common Nontuberculous Mycobacteria Directly from Clinical Specimens Using a Multiplex PCR Assayhttps://www.pharmaradar360.com/article/clinical-effect-evaluation-of-postoperative-complications-of-papillary-thyroid-c-e15681e655064329Pharma Surgeen2026-07-07T00:00:00.000ZClinical effect evaluation of postoperative complications of papillary thyroid carcinoma based on individualized intervention and prognostic analysis of precision nursing interventionhttps://www.pharmaradar360.com/article/lower-limb-rehabilitation-in-chronic-incomplete-sci-a-randomized-controlled-tria-08f26bc6c2d09e9fPharma Surgeen2026-07-07T00:00:00.000ZLower limb rehabilitation in chronic incomplete SCI: a randomized controlled trial protocol comparing combined TMS-tSCS neuromodulation vs. tSCS alonehttps://www.pharmaradar360.com/article/efficacy-of-tuina-combined-with-core-stability-training-on-lumbar-stability-and-bdb6a3716e71c6abPharma Surgeen2026-07-07T00:00:00.000ZEfficacy of Tuina combined with core stability training on lumbar stability and clinical outcomes in patients with lumbar disc herniation: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/clinical-mapps-a-personalized-healthcare-driven-assay-for-the-direct-identificat-94940eb62df59486Pharma Surgeen2026-07-07T00:00:00.000ZClinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patientshttps://www.pharmaradar360.com/article/anti-gpiiia-antibody-and-cd4-count-identify-an-autoimmune-enriched-phenotype-of-ffaf98eca1537687Pharma Surgeen2026-07-07T00:00:00.000ZAnti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogramhttps://www.pharmaradar360.com/article/a-testable-framework-linking-diagnostic-ai-contribution-to-outcome-measurement-i-925c62d5faa817c3Pharma Surgeen2026-07-07T00:00:00.000ZA testable framework linking diagnostic AI contribution to outcome measurement in clinical decision supporthttps://www.pharmaradar360.com/article/molecular-mechanisms-and-targeted-interventions-for-embolic-risk-in-cardiac-myxo-75b0c4899d2a4f5ePharma Surgeen2026-07-07T00:00:00.000ZMolecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translationhttps://www.pharmaradar360.com/article/translational-research-in-drug-development-challenges-and-opportunities-for-phar-90687ef205ddc998Pharma Surgeen2026-07-07T00:00:00.000ZTranslational research in drug development: challenges and opportunities for pharmacistshttps://www.pharmaradar360.com/article/measuring-safety-risks-in-online-drug-sales-empirical-study-based-on-complex-net-e43fbce0095f9570Pharma Surgeen2026-07-07T00:00:00.000ZMeasuring Safety Risks in Online Drug Sales: Empirical Study Based on Complex Network Theoryhttps://www.pharmaradar360.com/article/clinical-equivalence-of-privacy-preserving-federated-learning-a-consortium-block-6812ebbf9b764ad3Pharma Surgeen2026-07-07T00:00:00.000ZClinical Equivalence of Privacy-Preserving Federated Learning: A Consortium Blockchain Framework with Equivalence Testinghttps://www.pharmaradar360.com/article/the-spleen-negatively-regulates-the-acute-phase-of-experimental-autoimmune-encep-10ea362eca5dd100Pharma Surgeen2026-07-07T00:00:00.000ZThe Spleen Negatively Regulates the Acute Phase of Experimental Autoimmune Encephalomyelitis in Micehttps://www.pharmaradar360.com/article/optimizing-imatinib-sampling-strategies-through-a-population-approach-a-crucial-8ade5670abce53ebPharma Surgeen2026-07-07T00:00:00.000ZOptimizing imatinib sampling strategies through a population approach: a crucial step to model-informed precision dosing validation for point-of-care therapeutic drug monitoringhttps://www.pharmaradar360.com/article/mapping-the-safety-profile-of-histone-deacetylase-inhibitors-in-children-with-ca-48eb5a489fe067ecPharma Surgeen2026-07-07T00:00:00.000ZMapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancerhttps://www.pharmaradar360.com/article/correction-unintentional-benzodiazepine-use-and-frequency-of-drug-checking-servi-fe31100f59e79e20Pharma Surgeen2026-07-07T00:00:00.000ZCorrection: Unintentional benzodiazepine use and frequency of drug checking service utilization: a cross-sectional studyhttps://www.pharmaradar360.com/article/kif23-in-disease-pathogenesis-and-therapeutics-from-molecular-mechanisms-to-clin-5b453eae8f3e4e20Pharma Surgeen2026-07-07T00:00:00.000ZKIF23 in disease pathogenesis and therapeutics : from molecular mechanisms to clinical translationhttps://www.pharmaradar360.com/article/caregiver-led-versus-therapist-led-training-programme-for-caregivers-of-children-0c4ff0982abe07c0Pharma Surgeen2026-07-07T00:00:00.000ZCaregiver-led versus therapist-led training programme for caregivers of children with cerebral palsy in rural Malawi: a feasibility randomised controlled trialhttps://www.pharmaradar360.com/article/retrospective-analysis-of-the-clinical-characteristics-of-childhood-ocular-traum-5e4e891cda7fb8e7Pharma Surgeen2026-07-07T00:00:00.000ZRetrospective analysis of the clinical characteristics of childhood ocular trauma, 2020–2024https://www.pharmaradar360.com/article/ferroptosis-and-sepsis-induced-myocardial-injury-a-prospective-clinical-study-225855bb538dac1bPharma Surgeen2026-07-07T00:00:00.000ZFerroptosis and sepsis-induced myocardial injury: a prospective clinical studyhttps://www.pharmaradar360.com/article/assessing-the-treatment-of-male-infertility-through-principal-component-analysis-3b6cde70a3bb71e4Pharma Surgeen2026-07-07T00:00:00.000ZAssessing the treatment of male infertility through principal component analysis: a retrospective studyhttps://www.pharmaradar360.com/article/evolocumab-in-patients-with-prior-percutaneous-coronary-intervention-and-no-prio-aecfcaf5110af478Pharma Surgeen2026-07-07T00:00:00.000ZEvolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trialhttps://www.pharmaradar360.com/article/lifestyle-induced-visceral-fat-loss-as-a-key-target-for-durable-cardiometabolic-254b54946a0a1eabPharma Surgeen2026-07-07T00:00:00.000ZLifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trialshttps://www.pharmaradar360.com/article/family-functioning-and-medication-self-management-in-rural-older-adults-with-chr-6daae21099fa1b05Pharma Surgeen2026-07-07T00:00:00.000ZFamily Functioning and Medication Self‐Management in Rural Older Adults With Chronic Comorbidities: The Mediating Role of Self‐Efficacyhttps://www.pharmaradar360.com/article/developmental-patterns-and-clinical-relevance-of-os-trigonum-os-subfibulare-and-387db09ad6c556eePharma Surgeen2026-07-07T00:00:00.000ZDevelopmental Patterns and Clinical Relevance of Os Trigonum, Os Subfibulare, and Os Subtibiale in Young Athletes: A Cross-Sectional Study of 1,167 Athleteshttps://www.pharmaradar360.com/article/comment-on-effects-of-locally-applied-water-filtered-infrared-a-irradiation-adju-aea613ba30b63ea1Pharma Surgeen2026-07-07T00:00:00.000ZComment on ‘effects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud’s phenomenon – a randomized controlled trial’https://www.pharmaradar360.com/article/green-synthesis-of-tetrahydropyridine-3-carboxylate-derivatives-and-evaluation-o-ff3b58dacb597682Pharma Surgeen2026-07-07T00:00:00.000ZGreen synthesis of tetrahydropyridine-3-carboxylate derivatives and evaluation of antimicrobial and antimalarial activities supported by molecular docking, POM studies, and drug-likeness analysishttps://www.pharmaradar360.com/article/robust-higher-order-feedback-feedforward-ilc-for-networked-nonlinear-system-with-a55d5819d6b15e38Pharma Surgeen2026-07-07T00:00:00.000ZRobust higher-order feedback feedforward ILC for networked nonlinear system with varying trial lengths, data dropouts and disturbanceshttps://www.pharmaradar360.com/article/bispecific-10e8-4-imab-broadly-neutralizing-antibody-in-people-with-or-without-h-bd2f8ab82406ab0dPharma Surgeen2026-07-07T00:00:00.000ZBispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trialhttps://www.pharmaradar360.com/article/empowering-clinical-trial-design-with-agentic-intelligence-and-real-world-data-cc4c34f3683e4e50Pharma Surgeen2026-07-07T00:00:00.000ZEmpowering clinical trial design with agentic intelligence and real-world datahttps://www.pharmaradar360.com/article/measurable-residual-disease-is-not-a-universally-reliable-surrogate-for-progress-f64b95205d12bdfePharma Surgeen2026-07-07T00:00:00.000ZMeasurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapieshttps://www.pharmaradar360.com/article/renal-involvement-in-leprosy-in-the-multidrug-therapy-era-current-evidence-and-c-975ceba670a70b2aPharma Surgeen2026-07-07T00:00:00.000ZRenal Involvement in Leprosy in the Multidrug Therapy Era: Current Evidence and Clinical Monitoringhttps://www.pharmaradar360.com/article/genetic-control-of-hypocotyl-and-ray-floret-color-in-newly-developed-genetic-sto-1ca7b99227c515c5Pharma Surgeen2026-07-07T00:00:00.000ZGenetic control of hypocotyl and ray floret color in newly developed genetic stock PYRS-1 of sunflower and mapping of ray floret color loci using simple sequence repeat markershttps://www.pharmaradar360.com/article/complement-component-c4b-prioritization-through-drug-target-mendelian-randomizat-87176a51cf4536dfPharma Surgeen2026-07-07T00:00:00.000ZComplement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosishttps://www.pharmaradar360.com/article/multi-method-statistical-signal-aggregation-with-machine-learning-for-severity-c-13b8b5b1382f9dddPharma Surgeen2026-07-07T00:00:00.000ZMulti-method statistical signal aggregation with machine learning for severity classification of neonatal adverse drug reactionshttps://www.pharmaradar360.com/article/from-executor-to-orchestrator-the-pharmacology-scientist-in-the-age-of-agentic-s-8458c701b228ad16Pharma Surgeen2026-07-07T00:00:00.000ZFrom Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic <scp>AI</scp>https://www.pharmaradar360.com/article/novartis-adc-gambit-regulation-as-catalyst-for-u-k-biotech-a-biocentury-podcast-49fc1aa668df0c86Pharma Surgeen2026-07-06T23:16:00.000ZNovartis’ ADC gambit & regulation as catalyst for U.K. biotech — a BioCentury podcasthttps://www.pharmaradar360.com/article/fda-names-former-pharmaceutical-company-executive-to-oversee-us-drug-program-544f80cbdd268c7ePharma Surgeen2026-07-06T23:11:03.000ZFDA names former pharmaceutical company executive to oversee US drug programhttps://www.pharmaradar360.com/article/why-biotech-cos-need-litigation-plans-before-bad-news-8674770d1a50eb5bPharma Surgeen2026-07-06T22:12:00.000ZWhy Biotech Cos. Need Litigation Plans Before Bad Newshttps://www.pharmaradar360.com/article/opus-genetics-stock-holds-buy-rating-at-btig-on-gene-therapy-progress-by-investi-1b1f57ff64f043f8Pharma Surgeen2026-07-06T21:16:34.000ZOpus Genetics stock holds Buy rating at BTIG on gene therapy progress By Investing.comhttps://www.pharmaradar360.com/article/a-former-fda-official-on-antidepressants-and-suicide-risk-108b951f3d91f52bPharma Surgeen2026-07-06T21:08:54.000ZA former FDA official on antidepressants and suicide riskhttps://www.pharmaradar360.com/article/vertex-acquires-crinetics-pharmaceuticals-for-10-billion-as-biotech-m-a-booms-56f4cda432dae9ecPharma Surgeen2026-07-06T20:55:46.000ZVertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A boomshttps://www.pharmaradar360.com/article/to-be-labeled-a-success-econsent-must-deliver-on-promises-for-participants-sites-d9b08ffd97440a88Pharma Surgeen2026-07-06T20:23:43.000ZTo be Labeled a Success, eConsent Must Deliver on Promises for Participants, Sites, and Sponsorshttps://www.pharmaradar360.com/article/texas-biomed-teams-up-with-uk-based-biotech-company-to-fight-screwworm-c699c247130edca5Pharma Surgeen2026-07-06T19:25:00.000ZTexas Biomed teams up with UK-based biotech company to fight screwwormhttps://www.pharmaradar360.com/article/vera-therapeutics-jumps-9-as-fda-decision-on-kidney-drug-looms-27fce32923d30fb0Pharma Surgeen2026-07-06T19:06:00.000ZVera Therapeutics Jumps 9% as FDA Decision on Kidney Drug Loomshttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strat-5ab7787a8abc3c62Pharma Surgeen2026-07-06T19:00:00.000ZVERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategyhttps://www.pharmaradar360.com/article/cmps-stock-rises-23-pre-market-as-compass-achieves-primary-endpoint-in-phase-3-t-4191aa06fc271c3ePharma Surgeen2026-07-06T18:54:54.000ZCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trialhttps://www.pharmaradar360.com/article/mizuho-raises-revolution-stock-price-target-to-215-on-cancer-data-by-investing-c-573b023c9e2403a7Pharma Surgeen2026-07-06T18:23:43.000ZMizuho raises Revolution stock price target to $215 on cancer data By Investing.comhttps://www.pharmaradar360.com/article/b-riley-reiterates-buy-on-opus-genetics-stock-on-fda-alignment-by-investing-com-2caa3448242f6f2fPharma Surgeen2026-07-06T18:15:59.000ZB.Riley reiterates Buy on Opus Genetics stock on FDA alignment By Investing.comhttps://www.pharmaradar360.com/article/eli-lilly-and-vs-teva-which-pharmaceutical-stock-is-a-better-buy-in-2026-aa66898ab2b17046Pharma Surgeen2026-07-06T18:09:00.000ZEli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/novartis-buys-london-boston-biotech-for-up-to-1-5b-af92c8f25cce0ca2Pharma Surgeen2026-07-06T17:58:00.000ZNovartis buys London-Boston biotech for up to $1.5Bhttps://www.pharmaradar360.com/article/abbvie-announces-tepkinly-epcoritamab-in-combination-with-lenalidomide-and-ritux-3681d475b0e352acPharma Surgeen2026-07-06T17:45:00.000ZAbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphomahttps://www.pharmaradar360.com/article/new-partnership-aims-to-accelerate-development-of-cystic-fibrosis-therapy-04b5c8e9e0ccf64cPharma Surgeen2026-07-06T17:35:26.000ZNew partnership aims to accelerate development of cystic fibrosis therapyhttps://www.pharmaradar360.com/article/roche-pens-490m-astex-breast-cancer-license-deal-35a03c0939d092b6Pharma Surgeen2026-07-06T17:23:52.000ZRoche pens $490m Astex breast cancer license dealhttps://www.pharmaradar360.com/article/cordis-project-minimally-invasive-neuromodulation-implant-and-implantation-proce-6b9424108f032421Pharma Surgeen2026-07-06T17:23:31.000ZCORDIS project: Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disordershttps://www.pharmaradar360.com/article/the-new-rules-of-biotech-now-available-in-hardcover-and-audiobook-19cedd1e8096165aPharma Surgeen2026-07-06T17:23:10.000ZThe New Rules of Biotech Now Available in Hardcover and Audiobookhttps://www.pharmaradar360.com/article/cordis-project-integrated-services-for-infectious-disease-outbreak-research-53a1efcb4b0572e0Pharma Surgeen2026-07-06T17:21:40.000ZCORDIS project: Integrated Services for Infectious Disease Outbreak Researchhttps://www.pharmaradar360.com/article/cordis-project-smart-living-homes-whole-interventions-demonstrator-for-people-at-2c10cad06f08ec94Pharma Surgeen2026-07-06T17:06:07.000ZCORDIS project: SMART LIVING HOMES - WHOLE INTERVENTIONS DEMONSTRATOR FOR PEOPLE AT HEALTH AND SOCIAL RISKShttps://www.pharmaradar360.com/article/cordis-project-advancing-a-gmma-based-vaccine-against-invasive-non-typhoidal-sal-9be2f27526926dbcPharma Surgeen2026-07-06T17:06:04.000ZCORDIS project: Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africahttps://www.pharmaradar360.com/article/cordis-project-non-biased-fluorescent-dyes-as-markers-of-drugs-for-optical-in-ce-b2117c7245f75b0ePharma Surgeen2026-07-06T17:04:51.000ZCORDIS project: Non-biased fluorescent dyes as markers of drugs for optical in cellulo and in vivo imaginghttps://www.pharmaradar360.com/article/cordis-project-up-scaling-the-global-univocal-identification-of-medicines-72a91559ef9286baPharma Surgeen2026-07-06T17:04:45.000ZCORDIS project: Up-scaling the global univocal identification of medicineshttps://www.pharmaradar360.com/article/ataibeckley-completes-dosing-in-vls-01-depression-trial-by-investing-com-ede33bbfec44f8d1Pharma Surgeen2026-07-06T16:11:01.000ZAtaiBeckley completes dosing in VLS-01 depression trial By Investing.comhttps://www.pharmaradar360.com/article/inadvertent-vaccination-in-pregnancy-vip-778ef4ca08495cd2Pharma Surgeen2026-07-06T16:10:47.000ZInadvertent vaccination in pregnancy (VIP)https://www.pharmaradar360.com/article/new-survey-shows-collaboration-between-pharmaceutical-industry-and-uk-academia-i-9bd1328bcc9f738fPharma Surgeen2026-07-06T16:01:53.000ZNew survey shows collaboration between pharmaceutical industry and UK academia is growinghttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-9706a4da64751d8bPharma Surgeen2026-07-06T16:01:03.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/hsbc-drops-pfizer-to-hold-seagen-adc-miss-leaves-43b-bet-without-catalyst-0e9f1cb5149a8d59Pharma Surgeen2026-07-06T15:58:22.000ZHSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalysthttps://www.pharmaradar360.com/article/biosimilar-race-heats-up-for-48-trillion-keytruda-market-a00759221a387a14Pharma Surgeen2026-07-06T15:38:21.000ZBiosimilar Race Heats Up for $48 Trillion Keytruda Markethttps://www.pharmaradar360.com/article/novartis-acquires-u-k-cancer-biotech-myricx-bio-for-1-5-billion-2eecdc96b2721668Pharma Surgeen2026-07-06T15:38:12.000ZNovartis acquires U.K. cancer biotech Myricx Bio for $1.5 billionhttps://www.pharmaradar360.com/article/northwell-names-entrepreneur-dr-brian-kim-biotech-chief-0fd68213490ae0b1Pharma Surgeen2026-07-06T15:35:28.000ZNorthwell names entrepreneur Dr. Brian Kim biotech chiefhttps://www.pharmaradar360.com/article/why-are-drugmakers-racing-to-acquire-adc-payload-platforms-4d516a05bf02467dPharma Surgeen2026-07-06T15:31:55.000ZWhy Are Drugmakers Racing to Acquire ADC Payload Platforms?https://www.pharmaradar360.com/article/can-vibration-therapy-prevent-bone-loss-f28b4de5e5d8a606Pharma Surgeen2026-07-06T15:16:52.000ZCan vibration therapy prevent bone loss?https://www.pharmaradar360.com/article/astrazeneca-plc-stock-azn-moved-down-by-3-79-on-jul-6-what-signal-does-it-send-02b2bb6c686f7b27Pharma Surgeen2026-07-06T15:15:10.000ZAstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send?https://www.pharmaradar360.com/article/novartis-scoops-up-uk-biotech-myricx-in-1-5-billion-cancer-push-64d7440ff5c96e77Pharma Surgeen2026-07-06T15:13:20.000ZNovartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Pushhttps://www.pharmaradar360.com/article/milestone-alert-can-fite-completes-enrollment-in-phase-3-trial-of-oral-piclideno-1a6617f68a18c5c9Pharma Surgeen2026-07-06T15:08:34.000ZMilestone Alert: Can-Fite Completes Enrollment in Phase 3 Trial of Oral Piclidenoson for Psoriasishttps://www.pharmaradar360.com/article/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list-3f73690e7dd97803Pharma Surgeen2026-07-06T15:06:37.000ZFDA Panel to Evaluate 7 Popular Peptides for Compounding Substances Listhttps://www.pharmaradar360.com/article/incidental-cavitary-pulmonary-mycobacterium-avium-complex-disease-with-possible-db9bdc5aef660871Pharma Surgeen2026-07-06T15:06:04.000ZIncidental Cavitary Pulmonary Mycobacterium avium Complex Disease With Possible Haemophilus influenzae Coinfection and Pharmacologic Barriers to Therapy: A Case Reporthttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-ending-a-clinical-trial-8d7a41f1e7e1b46ePharma Surgeen2026-07-06T15:02:31.000ZClinical trials for medicines: ending a clinical trialhttps://www.pharmaradar360.com/article/hair-loss-biotech-veradermics-up-656-since-its-ipo-credits-the-obesity-boom-7d6933cace8ee817Pharma Surgeen2026-07-06T14:56:30.000ZHair loss biotech Veradermics, up 656% since its IPO, credits the obesity boomhttps://www.pharmaradar360.com/article/clinical-investigations-for-medical-devices-5b914eac61a14f9cPharma Surgeen2026-07-06T14:54:37.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/diphtheria-cases-among-asylum-seekers-in-england-2022-to-2026-3b388baae0a9b6b0Pharma Surgeen2026-07-06T14:50:54.000ZDiphtheria: cases among asylum seekers in England, 2022 to 2026https://www.pharmaradar360.com/article/new-haven-biotech-gets-one-year-notice-that-covid-therapy-s-emergency-authorizat-b1f482e9db6fb057Pharma Surgeen2026-07-06T14:38:14.000ZNew Haven biotech gets one-year notice that COVID therapy's emergency authorization will endhttps://www.pharmaradar360.com/article/the-ndaa-strengthens-government-support-for-biotech-it-can-be-even-stronger-59fff94b3e55ea54Pharma Surgeen2026-07-06T14:33:49.000ZThe NDAA Strengthens Government Support for Biotech. It Can Be Even Stronger.https://www.pharmaradar360.com/article/revolution-medicines-stock-hits-all-time-high-at-193-12-usd-ec310682154309b9Pharma Surgeen2026-07-06T14:29:28.000ZRevolution Medicines stock hits all-time high at 193.12 USDhttps://www.pharmaradar360.com/article/beyond-boston-unlikely-cities-stake-biotech-claims-c20c0c3b39ee70afPharma Surgeen2026-07-06T14:27:49.000ZBeyond Boston: Unlikely cities stake biotech claimshttps://www.pharmaradar360.com/article/the-evolution-and-impact-of-patient-support-services-a-strategic-framework-c6fe559337f961fePharma Surgeen2026-07-06T14:27:39.000ZThe Evolution and Impact of Patient Support Services: A Strategic Frameworkhttps://www.pharmaradar360.com/article/vertex-signs-letter-of-intent-loi-with-the-pan-canadian-pharmaceutical-alliance-7388369e90cd40daPharma Surgeen2026-07-06T14:22:00.000ZVertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosishttps://www.pharmaradar360.com/article/first-in-class-oral-piclidenoson-reaches-pivotal-phase-3-enrollment-milestone-in-746fca67fa239490Pharma Surgeen2026-07-06T14:03:03.000ZFirst-in-Class Oral Piclidenoson Reaches Pivotal Phase 3 Enrollment Milestone in Plaque Psoriasishttps://www.pharmaradar360.com/article/aspen-athletics-club-delivers-inspiring-performance-at-the-comrades-marathon-d6ebbc6193b7bef6Pharma Surgeen2026-07-06T14:01:04.000ZAspen Athletics Club delivers inspiring performance at the Comrades Marathonhttps://www.pharmaradar360.com/article/katalyze-ai-raises-10-5m-to-build-the-agentic-operating-system-for-pharmaceutica-a75405fb33223dcdPharma Surgeen2026-07-06T14:00:15.000ZKatalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/why-this-biotech-up-14-since-its-breakout-is-on-the-rise-once-again-3cb9c7faa1ef94e0Pharma Surgeen2026-07-06T14:00:00.000ZWhy This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Againhttps://www.pharmaradar360.com/article/regulatory-round-up-6-july-2026-a22ea0d2cf013ab4Pharma Surgeen2026-07-06T13:59:11.000ZRegulatory round-up: 6 July 2026https://www.pharmaradar360.com/article/four-major-biotech-updates-to-catch-up-on-5a45ac9fa2c61372Pharma Surgeen2026-07-06T13:39:14.000ZFour major biotech updates to catch up onhttps://www.pharmaradar360.com/article/novartis-to-buy-uk-oncology-biotech-for-up-to-1-5b-35ee66dd13d5e31aPharma Surgeen2026-07-06T13:37:00.000ZNovartis To Buy UK Oncology Biotech For Up To $1.5Bhttps://www.pharmaradar360.com/article/amp-bgtc-announces-fda-clearance-of-investigational-new-drug-application-for-gen-97e24ead04790a0fPharma Surgeen2026-07-06T13:34:58.000ZAMP® BGTC Announces FDA Clearance of Investigational New Drug Application for Gene Therapy Targeting Multiple Sulfatase Deficiencyhttps://www.pharmaradar360.com/article/improved-early-warning-systems-needed-to-reduce-medicines-supply-risks-says-abpi-a935581b9ac904b1Pharma Surgeen2026-07-06T13:25:28.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPIhttps://www.pharmaradar360.com/article/abpi-celebrates-a-month-of-major-investment-commitments-into-uk-life-sciences-1c69d1d3b7170c47Pharma Surgeen2026-07-06T13:24:40.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/the-uk-should-seek-to-be-a-european-leader-for-rare-disease-medicine-says-new-re-2c00695aa8f36f31Pharma Surgeen2026-07-06T13:24:23.000ZThe UK should seek to be a European leader for rare disease medicine, says new reporthttps://www.pharmaradar360.com/article/life-sciences-sector-policy-delivery-1ed23c307a91887dPharma Surgeen2026-07-06T13:24:11.000ZLife Sciences Sector Policy Deliveryhttps://www.pharmaradar360.com/article/unlocking-nhs-data-to-increase-recruitment-into-clinical-trials-will-give-the-uk-8e6c13b135f9d747Pharma Surgeen2026-07-06T13:23:56.000ZUnlocking NHS data to increase recruitment into clinical trials will give the UK a competitive edge, says ABPIhttps://www.pharmaradar360.com/article/abpi-response-to-publication-of-england-s-rare-diseases-action-plan-2026-0f3502b175976952Pharma Surgeen2026-07-06T13:23:45.000ZABPI response to publication of England's Rare Diseases Action Plan 2026https://www.pharmaradar360.com/article/new-report-underlines-the-health-and-economic-opportunity-from-boosting-industry-a999f4c8c6537543Pharma Surgeen2026-07-06T13:23:34.000ZNew report underlines the health and economic opportunity from boosting industry clinical trialshttps://www.pharmaradar360.com/article/abpi-comment-on-measles-outbreak-and-childhood-vaccination-cffce6d42f542a83Pharma Surgeen2026-07-06T13:23:22.000ZABPI comment on measles outbreak and childhood vaccinationhttps://www.pharmaradar360.com/article/uk-opportunity-to-accelerate-development-of-new-medicines-4d0b479434d83278Pharma Surgeen2026-07-06T13:23:00.000ZUK opportunity to accelerate development of new medicineshttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-06T13:22:58.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/abpi-response-to-national-cancer-plan-04cbac4225883744Pharma Surgeen2026-07-06T13:22:49.000ZABPI response to National Cancer Planhttps://www.pharmaradar360.com/article/what-fda-s-ai-warning-letter-tells-us-about-gmp-accountability-37a3cd780e7c38acPharma Surgeen2026-07-06T13:16:55.000ZWhat FDA's AI Warning Letter Tells Us About GMP Accountabilityhttps://www.pharmaradar360.com/article/opus-genetics-aligns-with-fda-on-phase-3-trial-for-lca5-therapy-by-investing-com-ef71c98f85316df4Pharma Surgeen2026-07-06T13:16:54.000ZOpus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy By Investing.comhttps://www.pharmaradar360.com/article/vivos-otc-market-code-rdgl-has-received-investigational-device-exemption-ide-app-c7a7ee1dd07bf73bPharma Surgeen2026-07-06T13:10:16.000ZVivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.https://www.pharmaradar360.com/article/opinion-san-diego-helped-invent-biotech-and-must-now-fight-to-keep-it-cc0ee24c18115c03Pharma Surgeen2026-07-06T13:08:37.000ZOpinion: San Diego helped invent biotech and must now fight to keep ithttps://www.pharmaradar360.com/article/biotech-alliance-ramps-up-drug-pricing-lobbying-e6b857e82e712c69Pharma Surgeen2026-07-06T12:54:07.000ZBiotech Alliance Ramps Up Drug Pricing Lobbyinghttps://www.pharmaradar360.com/article/early-stage-scribe-wants-to-write-ipo-story-even-as-investors-favor-derisked-por-ed871922977e8167Pharma Surgeen2026-07-06T12:51:25.000ZEarly-stage Scribe wants to write IPO story even as investors favor derisked portfolioshttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-bio-for-up-to-1-5b-8751b8a295c63084Pharma Surgeen2026-07-06T12:50:59.000ZNovartis to buy UK biotech Myricx Bio for up to $1.5Bhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-06T12:48:58.000ZVeraxa Biotech (VRXA) Stock Price, News & Analysishttps://www.pharmaradar360.com/article/neurosense-joins-als-expert-webinar-on-primec-and-phase-3-plans-640d232c0ed810e7Pharma Surgeen2026-07-06T12:45:00.000ZNeuroSense joins ALS expert webinar on PrimeC and Phase 3 planshttps://www.pharmaradar360.com/article/moleculin-biotech-ceo-discusses-preliminary-miracle-trial-results-for-annamycin-ac67339453186b66Pharma Surgeen2026-07-06T12:44:00.000ZMoleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segmenthttps://www.pharmaradar360.com/article/incyte-pays-1-25b-for-vega-adding-a-phase-3-bleeding-disorder-drug-c9a50a82b86313daPharma Surgeen2026-07-06T12:41:37.000ZIncyte pays $1.25B for Vega, adding a Phase 3 bleeding-disorder drughttps://www.pharmaradar360.com/article/veraxa-biotech-targets-2028-ind-filing-for-lead-candidate-77698e5440cd3521Pharma Surgeen2026-07-06T12:36:16.000ZVERAXA Biotech targets 2028 IND filing for lead candidatehttps://www.pharmaradar360.com/article/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone-with-completion-of-pat-ea81d9eaee6d31fcPharma Surgeen2026-07-06T12:35:40.000ZCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027https://www.pharmaradar360.com/article/fda-clears-vivos-to-test-radiogel-in-first-u-s-cancer-patients-f61b2b5e8f568cf3Pharma Surgeen2026-07-06T12:30:00.000ZFDA clears Vivos to test RadioGel in first U.S. cancer patientshttps://www.pharmaradar360.com/article/vivos-inc-otcqb-rdgl-receives-u-s-fda-approval-for-11e444f015794bf7Pharma Surgeen2026-07-06T12:30:00.000ZVivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval forhttps://www.pharmaradar360.com/article/kingdom-advances-biotech-ties-at-us-convention-9592ed358c453bbfPharma Surgeen2026-07-06T12:16:46.000ZKingdom advances biotech ties at US conventionhttps://www.pharmaradar360.com/article/inclusion-of-disadvantaged-communities-in-public-health-research-74c06688c67d0245Pharma Surgeen2026-07-06T12:14:23.000ZInclusion of disadvantaged communities in public health researchhttps://www.pharmaradar360.com/article/u-s-department-of-health-and-human-services-and-the-u-s-food-and-drug-administra-b173ff1f261647f9Pharma Surgeen2026-07-06T12:05:42.000ZU.S. Department of Health and Human Services and the U.S. Food and Drug Administration Commend DEA Action Against Certain Kratom-Related Substances, 7-OH Productshttps://www.pharmaradar360.com/article/immuron-nasdaq-imrn-advances-imm-529-cdi-drug-with-new-partnering-push-91ff178910bfb94aPharma Surgeen2026-07-06T12:01:45.000ZImmuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering pushhttps://www.pharmaradar360.com/article/startups-move-to-colorado-amid-concerns-state-losing-its-luster-for-tech-compani-f2585701a2664d76Pharma Surgeen2026-07-06T12:00:57.000ZStartups move to Colorado amid concerns state losing its luster for tech companieshttps://www.pharmaradar360.com/article/jamp-chlorthalidone-12-5-mg-tablet-out-of-specification-dissolution-18615140b2ce88f6Pharma Surgeen2026-07-06T12:00:00.000ZJAMP Chlorthalidone 12.5 mg tablet: Out of specification (Dissolution)https://www.pharmaradar360.com/article/hotline-iv-fluid-warmer-system-accessories-0a98a45eff8b70b9Pharma Surgeen2026-07-06T12:00:00.000ZHotline IV Fluid Warmer System & Accessorieshttps://www.pharmaradar360.com/article/opus-genetics-aligns-with-fda-on-phase-3-trial-for-lca5-therapy-a60944de8196fc3bPharma Surgeen2026-07-06T11:57:45.000ZOpus Genetics aligns with FDA on Phase 3 trial for LCA5 therapyhttps://www.pharmaradar360.com/article/scribe-notes-down-ipo-ambition-to-fund-lipid-lowering-genetic-meds-through-clini-82a7242a1fdef07bPharma Surgeen2026-07-06T11:54:55.000ZScribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trialshttps://www.pharmaradar360.com/article/trump-easing-testosterone-restrictions-sparks-health-warnings-over-radical-plan-baa4d8b8d93dc862Pharma Surgeen2026-07-06T11:49:56.000ZTrump Easing Testosterone Restrictions Sparks Health Warnings Over Radical Plan To Pump Up Men's Declining Hormone Levelshttps://www.pharmaradar360.com/article/fda-accepts-pharvaris-nda-for-oral-hae-attack-treatment-drug-fcd79fe3f0978c18Pharma Surgeen2026-07-06T11:42:11.000ZFDA accepts Pharvaris NDA for oral HAE attack treatment drughttps://www.pharmaradar360.com/article/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-437bcf42f4b37b81Pharma Surgeen2026-07-06T11:40:29.000ZAlzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in Londonhttps://www.pharmaradar360.com/article/caris-life-sciences-launches-cancer-blood-test-caris-detect-fa4f1a0c066c49d5Pharma Surgeen2026-07-06T11:40:24.000ZCaris Life Sciences launches cancer blood test ‘Caris Detect’https://www.pharmaradar360.com/article/germany-modifies-healthcare-reforms-to-ease-burden-on-pharma-d492ac8514075061Pharma Surgeen2026-07-06T11:26:12.000ZGermany Modifies Healthcare Reforms to Ease Burden on Pharmahttps://www.pharmaradar360.com/article/opus-genetics-aligns-with-fda-on-phase-3-trial-for-lca5-therapy-20b0af33bd10222bPharma Surgeen2026-07-06T11:20:05.000ZOpus Genetics aligns with FDA on Phase 3 trial for LCA5 therapyhttps://www.pharmaradar360.com/article/call-for-urgency-to-deliver-on-global-pledge-for-antibiotic-incentives-8410651fcfb2fb21Pharma Surgeen2026-07-06T11:17:46.000ZCall for urgency to deliver on global pledge for antibiotic incentiveshttps://www.pharmaradar360.com/article/abpi-welcome-the-appointment-of-sir-hugh-taylor-to-key-role-in-voluntary-scheme-39056310c3c2adaePharma Surgeen2026-07-06T11:17:24.000ZABPI welcome the appointment of Sir Hugh Taylor to key role in Voluntary Scheme negotiationshttps://www.pharmaradar360.com/article/abpi-response-to-mhra-clinical-trials-framework-e80894ced2632da3Pharma Surgeen2026-07-06T11:17:11.000ZABPI response to MHRA clinical trials frameworkhttps://www.pharmaradar360.com/article/novo-nordisk-is-suspended-from-abpi-membership-1915d3064720b506Pharma Surgeen2026-07-06T11:16:58.000ZNovo Nordisk is suspended from ABPI membershiphttps://www.pharmaradar360.com/article/abpi-response-to-the-budget-8187ce9f0eb61de7Pharma Surgeen2026-07-06T11:16:42.000ZABPI response to the Budgethttps://www.pharmaradar360.com/article/abpi-welcomes-new-nhs-research-guidance-c5e2fd624c5585f4Pharma Surgeen2026-07-06T11:16:02.000ZABPI welcomes new NHS research guidancehttps://www.pharmaradar360.com/article/susan-rienow-of-pfizer-confirmed-as-president-of-the-abpi-377b62fd55e5be7ePharma Surgeen2026-07-06T11:15:49.000ZSusan Rienow of Pfizer confirmed as President of the ABPIhttps://www.pharmaradar360.com/article/abpi-refreshes-its-commitment-to-improve-public-involvement-in-research-f8b745e29aa13989Pharma Surgeen2026-07-06T11:15:36.000ZABPI refreshes its commitment to improve public involvement in researchhttps://www.pharmaradar360.com/article/veraxa-biotech-targets-2028-ind-filing-for-lead-candidate-by-investing-com-d31c4febc8681324Pharma Surgeen2026-07-06T11:15:05.000ZVERAXA Biotech targets 2028 IND filing for lead candidate By Investing.comhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-provides-pipeline-and-partnering-update-advances-bitac-develop-ee42babd2c9a876bPharma Surgeen2026-07-06T11:12:00.000ZVERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategyhttps://www.pharmaradar360.com/article/can-fite-biopharma-announces-completion-of-enrollment-of-first-247-patients-in-p-257dce2d449400c0Pharma Surgeen2026-07-06T11:12:00.000ZCan-Fite BioPharma Announces Completion of Enrollment of First 247 Patients in Pivotal Phase 3 Piclidenoson Psoriasis Study Ahead of Interim Analysishttps://www.pharmaradar360.com/article/belite-bio-announces-tinlarebant-phase-3-dragon-study-results-to-be-presented-at-b847c1bd26db4537Pharma Surgeen2026-07-06T11:12:00.000ZBelite Bio Announces Tinlarebant Phase 3 DRAGON Study Results to Be Presented at ISCEV 2026 and ASRS 2026 Meetingshttps://www.pharmaradar360.com/article/opus-genetics-reaches-fda-alignment-on-phase-3-design-for-opgx-lca5-bla-may-be-s-a7209b25c8151a6cPharma Surgeen2026-07-06T11:12:00.000ZOpus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Datahttps://www.pharmaradar360.com/article/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-emergency-use-auth-c2a83c7978ea76d9Pharma Surgeen2026-07-06T11:08:15.000ZInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAhttps://www.pharmaradar360.com/article/opus-genetics-announces-fda-alignment-on-phase-3-registrational-trial-design-for-83bff0a95308e338Pharma Surgeen2026-07-06T11:07:44.000ZOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Diseasehttps://www.pharmaradar360.com/article/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir-697e735ef0213b03Pharma Surgeen2026-07-06T11:07:37.000ZPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attackshttps://www.pharmaradar360.com/article/can-fite-nyse-american-canf-reaches-key-phase-3-psoriasis-interim-analysis-miles-8e5e833a964b01a8Pharma Surgeen2026-07-06T11:03:38.000ZCan-Fite (NYSE American: CANF) reaches key Phase 3 psoriasis interim analysis milestonehttps://www.pharmaradar360.com/article/pemgarda-faces-2027-eua-end-as-invivyd-talks-next-steps-with-fda-ea8b03d54596a588Pharma Surgeen2026-07-06T11:01:00.000ZPEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDAhttps://www.pharmaradar360.com/article/fda-accepts-pharvaris-nda-for-oral-hae-attack-treatment-drug-by-investing-com-ebefbc7c57bba31dPharma Surgeen2026-07-06T11:00:03.000ZFDA accepts Pharvaris NDA for oral HAE attack treatment drug By Investing.comhttps://www.pharmaradar360.com/article/ionis-finishes-key-enrollment-step-for-angelman-syndrome-drug-trial-9879f13ebe96aaa6Pharma Surgeen2026-07-06T11:00:00.000ZIonis finishes key enrollment step for Angelman syndrome drug trialhttps://www.pharmaradar360.com/article/belite-bio-takes-phase-3-stargardt-disease-data-to-two-eye-meetings-3a40c685b2536738Pharma Surgeen2026-07-06T11:00:00.000ZBelite Bio takes Phase 3 Stargardt disease data to two eye meetingshttps://www.pharmaradar360.com/article/can-fite-s-psoriasis-study-reaches-interim-analysis-after-247-patients-enrolled-2d2c99ffafabf338Pharma Surgeen2026-07-06T11:00:00.000ZCan-Fite’s psoriasis study reaches interim analysis after 247 patients enrolledhttps://www.pharmaradar360.com/article/opus-genetics-clears-fda-design-for-phase-3-trial-in-childhood-blindness-32e9e777f25a5955Pharma Surgeen2026-07-06T11:00:00.000ZOpus Genetics clears FDA design for Phase 3 trial in childhood blindnesshttps://www.pharmaradar360.com/article/veraxa-says-its-bitac-cancer-pipeline-is-drawing-partner-interest-5e5daa943376e675Pharma Surgeen2026-07-06T11:00:00.000ZVERAXA says its BiTAC cancer pipeline is drawing partner interesthttps://www.pharmaradar360.com/article/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone-with-completion-of-pat-7b17e29fb7858796Pharma Surgeen2026-07-06T11:00:00.000ZCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027https://www.pharmaradar360.com/article/ionis-completes-enrollment-in-pivotal-cohort-of-the-phase-3-reveal-study-evaluat-d27c4fb074a833a7Pharma Surgeen2026-07-06T11:00:00.000ZIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndromehttps://www.pharmaradar360.com/article/pharvaris-announces-fda-acceptance-of-nda-for-deucrictibant-ir-capsule-for-on-de-5d9a196c6312ea2ePharma Surgeen2026-07-06T11:00:00.000ZPharvaris Announces FDA Acceptance of NDA for Deucrictibant IR Capsule for On-Demand Treatment of HAE Attackshttps://www.pharmaradar360.com/article/pharvaris-wins-fda-review-for-oral-hae-attack-treatment-3314d800712b5914Pharma Surgeen2026-07-06T10:50:00.000ZPharvaris wins FDA review for oral HAE attack treatmenthttps://www.pharmaradar360.com/article/swiss-drugmaker-novartis-buys-uk-biotech-firm-in-1-5bn-deal-19b02ea12f163d29Pharma Surgeen2026-07-06T10:49:15.000ZSwiss drugmaker Novartis buys UK biotech firm in $1.5bn dealhttps://www.pharmaradar360.com/article/maharashtra-fda-tightens-milk-safety-rules-7039750cf431b278Pharma Surgeen2026-07-06T10:48:18.000ZMaharashtra FDA tightens milk safety ruleshttps://www.pharmaradar360.com/article/maharashtra-fda-flags-three-beauty-creams-over-toxic-mercury-and-lead-levels-e704186be85e7b80Pharma Surgeen2026-07-06T10:20:45.000ZMaharashtra FDA flags three beauty creams over toxic mercury and lead levelshttps://www.pharmaradar360.com/article/nhs-sets-first-ever-staff-standards-to-tackle-racism-and-violence-12a37bcb5ba604c4Pharma Surgeen2026-07-06T10:13:00.000ZNHS sets first-ever staff standards to tackle racism and violencehttps://www.pharmaradar360.com/article/ataibeckley-announces-last-patient-dosed-in-phase-2b-elumina-trial-of-vls-01-for-639f4cd3193a7147Pharma Surgeen2026-07-06T10:11:00.000ZAtaiBeckley Announces Last Patient Dosed in Phase 2b Elumina Trial of VLS-01 for Treatment-Resistant Depression; Topline Data Expected in Q4 2026https://www.pharmaradar360.com/article/novartis-to-acquire-myricx-bio-in-up-to-1-5bn-deal-c0896510ee5612eaPharma Surgeen2026-07-06T10:08:54.000ZNovartis to acquire Myricx Bio in up to $1.5bn dealhttps://www.pharmaradar360.com/article/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-ea876d4d4ce778c8Pharma Surgeen2026-07-06T10:07:09.000ZImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategyhttps://www.pharmaradar360.com/article/should-dayquil-be-legal-6ed5ddb208bb649ePharma Surgeen2026-07-06T10:06:46.000ZShould DayQuil be legal?https://www.pharmaradar360.com/article/reshoring-pharma-and-biotech-manufacturing-ahead-of-this-summer-s-tariff-deadlin-6b32118f49560292Pharma Surgeen2026-07-06T10:02:27.000ZReshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Lasthttps://www.pharmaradar360.com/article/toxic-fairness-creams-linked-to-kidney-disease-in-18-women-6878c877e955907bPharma Surgeen2026-07-06T10:01:16.000ZToxic Fairness Creams Linked to Kidney Disease in 18 Womenhttps://www.pharmaradar360.com/article/immuron-seeks-partner-for-gut-infection-drug-imm-529-c7b751e144b4b4f0Pharma Surgeen2026-07-06T10:00:00.000ZImmuron seeks partner for gut infection drug IMM-529https://www.pharmaradar360.com/article/a-decade-in-deals-houston-biotech-vc-deals-gradually-increasing-after-ups-and-do-fe3f0df4454cdd87Pharma Surgeen2026-07-06T10:00:00.000ZA decade in deals: Houston biotech VC deals gradually increasing after ups and downshttps://www.pharmaradar360.com/article/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-8c2939d28114cbcaPharma Surgeen2026-07-06T10:00:00.000ZAlzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in Londonhttps://www.pharmaradar360.com/article/5-biotech-stocks-that-delivered-100-to-300-gains-did-your-winning-trades-offset-d034e442512d022bPharma Surgeen2026-07-06T09:51:00.000Z5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?https://www.pharmaradar360.com/article/departmental-minute-on-public-dividend-capital-write-off-2025-to-2026-e362405845de73d3Pharma Surgeen2026-07-06T09:46:09.000ZDepartmental minute on public dividend capital write-off: 2025 to 2026https://www.pharmaradar360.com/article/newsletter-20-df9bc8c342e9de8fPharma Surgeen2026-07-06T09:38:22.000ZNewsletter #20https://www.pharmaradar360.com/article/germany-modifies-healthcare-reforms-to-ease-burden-on-pharma-3b31af9ccf0c0d7cPharma Surgeen2026-07-06T09:23:49.000ZGermany Modifies Healthcare Reforms to Ease Burden on Pharmahttps://www.pharmaradar360.com/article/maharashtra-fda-mandates-free-potable-water-in-all-hotels-and-restaurants-317f18e4dabbe072Pharma Surgeen2026-07-06T09:12:43.000ZMaharashtra FDA Mandates Free Potable Water in All Hotels and Restaurantshttps://www.pharmaradar360.com/article/novartis-to-pay-1-1b-upfront-for-myricx-to-expand-adc-pipeline-30acd7817780d25aPharma Surgeen2026-07-06T09:10:00.000ZNovartis to pay $1.1B upfront for Myricx to expand ADC pipelinehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-edesa-biotech-inc-nasdaq-edsa-0b3a9b3f40ef48ccPharma Surgeen2026-07-06T09:05:52.000ZEnterprise value to EBIT forward of Edesa Biotech, Inc. – NASDAQ:EDSAhttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-c40ee43363d9a479Pharma Surgeen2026-07-06T09:00:02.000ZMeningococcal B (MenB) time limited vaccination offerhttps://www.pharmaradar360.com/article/how-evogene-is-changing-the-future-for-the-pharma-and-agriculture-markets-5efe6d7c986d8dc6Pharma Surgeen2026-07-06T08:57:31.000ZHow Evogene is changing the future for the pharma and agriculture marketshttps://www.pharmaradar360.com/article/korea-pharma-biotech-stocks-head-for-event-driven-second-half-a2cc44035f1cfa5dPharma Surgeen2026-07-06T08:54:44.000ZKorea Pharma, Biotech Stocks Head for Event-Driven Second Halfhttps://www.pharmaradar360.com/article/i-spoke-to-anthropic-s-ceo-about-how-ai-may-affect-biotech-here-s-what-i-learned-9fad86120fd8512ePharma Surgeen2026-07-06T08:33:59.000ZI spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learnedhttps://www.pharmaradar360.com/article/zhejiang-conba-pharmaceutical-s-subsidiaries-sign-licensing-agreement-with-adneu-7fb287f36e3d745bPharma Surgeen2026-07-06T08:32:59.000ZZhejiang CONBA Pharmaceutical's Subsidiaries Sign Licensing Agreement With Adneurishttps://www.pharmaradar360.com/article/greater-bay-area-emerges-as-launchpad-for-china-s-biotech-rise-a0ff1a14c3c11672Pharma Surgeen2026-07-06T08:31:10.000ZGreater Bay Area emerges as launchpad for China's biotech risehttps://www.pharmaradar360.com/article/nhs-staff-standards-bb9d2a72502e72d3Pharma Surgeen2026-07-06T08:30:06.000ZNHS staff standardshttps://www.pharmaradar360.com/article/novartis-buys-uk-adc-biotech-myricx-bio-in-up-to-1-5bn-deal-5a88d5fca3fe183cPharma Surgeen2026-07-06T08:23:23.000ZNovartis buys UK ADC biotech Myricx Bio in up to $1.5bn dealhttps://www.pharmaradar360.com/article/price-to-book-forward-of-beijing-beilu-pharmaceutical-co-ltd-class-a-szse-300016-f708a92f2d348cc1Pharma Surgeen2026-07-06T08:07:51.000ZPrice to book forward of Beijing Beilu Pharmaceutical Co., Ltd. Class A – SZSE:300016https://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-pak-origin-goree-fairness-creams-two-others-ove-9c973f588155b31dPharma Surgeen2026-07-06T07:57:26.000ZMaharashtra FDA orders recall of Pak-origin Goree fairness creams, two others over toxic mercury, lead levelshttps://www.pharmaradar360.com/article/elevation-point-wealth-partners-llc-makes-new-1-33-million-investment-in-teva-ph-00528a127c4a505aPharma Surgeen2026-07-06T07:55:31.000ZElevation Point Wealth Partners LLC Makes New $1.33 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-4916613f488c7a16Pharma Surgeen2026-07-06T07:48:54.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-bio-in-1-5bn-deal-ab3db980af7aeca2Pharma Surgeen2026-07-06T07:46:19.000ZNovartis to buy UK biotech Myricx Bio in $1.5bn dealhttps://www.pharmaradar360.com/article/celltrion-files-amendment-for-u-s-phase-3-trial-of-keytruda-biosimilar-ct-p51-7e387284880d63f6Pharma Surgeen2026-07-06T07:44:51.000ZCelltrion Files Amendment for U.S. Phase 3 Trial of Keytruda Biosimilar CT-P51